

Supplementary Table 1. Changes in the continuous glucose monitoring variables from baseline to week 12 in patients aged ≥ 70 years

Parameter	Teneligliptin (n=16)	Placebo (n=16)	Between-group difference (95% CI)	P value ^c
Mean glucose, mg/dL				
Baseline ^a	175.1±21.6	179.1±28.2		
Change from baseline ^b	-30.0±5.2	-9.2±4.4	-20.9 (-33.6 to -8.2)	0.002
CV, %				
Baseline ^a	27.3±8.1	25.7±5.1		
Change from baseline ^b	-3.2±1.6	-1.3±1.4	-1.8 (-5.6 to 2.0)	0.332
SD, mg/dL				
Baseline ^a	47.2±13.7	45.9±11.0		
Change from baseline ^b	-13.3±2.5	-4.8±2.4	-8.4 (-15.3 to -1.6)	0.018
MAGE, mg/dL				
Baseline ^a	114.6±35.7	111.7±27.6		
Change from baseline ^b	-29.2±7.3	-10.7±6.3	-18.5 (-35.6 to -1.4)	0.035
TIR70–180 mg/dL, %				
Baseline ^a	57.4±17.9	54.9±22.5		
Change from baseline ^b	23.7±4.1	9.2±3.5	14.6 (4.7 to 24.4)	0.005
TAR > 250 mg/dL, %				
Baseline ^a	8.4±7.3	10.2±10.3		
Change from baseline ^b	-7.8±1.6	-2.9±1.3	-4.9 (-8.6 to -1.1)	0.013
TAR > 180 mg/dL, %				
Baseline ^a	38.9±17.6	41.8±22.1		
Change from baseline ^b	-23.9±3.6	-9.6±3.1	-14.4 (-23.3 to -5.5)	0.003
TBR < 70 mg/dL, %				
Baseline ^a	0.3±1.1	0.3±0.8		
Change from baseline ^b	-0.3±0.5	0.3±0.4	-0.6 (-1.7 to 0.6)	0.305
TBR < 54 mg/dL, %				
Baseline ^a	0.1±0.1	0.1±0.1		
Change from baseline ^b	-0.1±0.4	0.5±0.3	-0.6 (-1.6 to 0.3)	0.165

Values are presented as mean \pm standard deviation or least squares mean \pm standard error.

CI, confidence interval; CV, coefficient of variation; SD, standard deviation; MAGE, mean amplitude of glycemic excursion; TIR, time in target glucose range; TAR, time above target glucose range; TBR, time below target glucose range.

^aWilcoxon rank-sum test, ^bLeast squares mean \pm standard error, ^cAnalysis of covariance (ANCOVA) with baseline values and stratification factors (at randomization) as covariates.